Revisiting the pharmacodynamic uroselectivity of a1-adrenergic receptor antagonists

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorFederal University of Rio de Janeiro-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversidade de Brasília (UnB)-
Autor(es): dc.creatorQuaresma, Bruna Maria Castro Salomão-
Autor(es): dc.creatorPimenta, Amanda Reis-
Autor(es): dc.creatorSantos da Silva, Anne Caroline-
Autor(es): dc.creatorPupo, André Sampaio [UNESP]-
Autor(es): dc.creatorRomeiro, Luiz Antonio S.-
Autor(es): dc.creatorSilva, Claudia Lucia Martins-
Autor(es): dc.creatorNoël, François-
Data de aceite: dc.date.accessioned2022-02-22T00:32:51Z-
Data de disponibilização: dc.date.available2022-02-22T00:32:51Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2019-01-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1124/jpet.119.260216-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/201189-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/201189-
Descrição: dc.descriptiona1-Adrenoceptor (AR) antagonists are widely used for the relief of urinary retention secondary to benign prostatic hyperplasia (BPH). While the five Food and Drug Administration–approved a1-AR antagonists (terazosin, doxazosin, alfuzosin, tamsulosin, and silodosin) share similar efficacy, they differ in tolerability, with reports of ejaculatory dysfunction. The aim of the present work was to revisit their a1-AR subtype selectivity as well as of LDT5 (1-(2-methoxyphenyl)-4-[2-(3,4-dimethox-yphenyl) ethyl]piperazine monohydrochloride), a compound previously described as a multitarget antagonist of a1A-/a1D-AR and 5-HT1A receptors, and to estimate their affinity for D2, D3, and 5-HT1A receptors, which are putatively involved in ejaculatory dysfunction. Competition binding assays were performed with native (D2, 5-HT1A) or transfected (human a1A-, a1B-, a1Dt-AR, and D3) receptors for determination of the drug’s affinities. Tamsulosin and silodosin have the highest affinities for a1A-AR, but only silodosin is clearly a selective a1A-AR antagonist, with Ki ratios of 25.3 and 50.2 for the a1D- and a1B-AR, respectively. Tamsulosin, silodosin, and LDT5 (but not terazosin, doxazosin, and alfuzosin) have high affinity for the 5-HT1A receptor (Ki around 5–10 nM), behaving as antagonists. We conclude that the uroselectivity of tamsulosin is not explained by its too-low selectivity for the a1A- versus a1B-AR, and that its affinity for D2 and D3 receptors is probably too low for explaining the ejaculatory dysfunction reported for this drug. Present data also support the design of “better-than-LDT5” new multitarget lead compounds with pharmacokinetic selectivity based on poor brain penetration and that could prevent hyperplastic cell proliferation and BPH progression.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)-
Descrição: dc.descriptionLaboratory of Biochemical and Molecular Pharmacology Institute of Biomedical Sciences Federal University of Rio de Janeiro, Av Carlos Chagas Filho, 373-
Descrição: dc.descriptionDepartment of Pharmacology Instituto de Biociências UNESP-
Descrição: dc.descriptionHealth Sciences Faculty Universidade de Brasília-
Descrição: dc.descriptionDepartment of Pharmacology Instituto de Biociências UNESP-
Formato: dc.format106-112-
Idioma: dc.languageen-
Relação: dc.relationJournal of Pharmacology and Experimental Therapeutics-
???dc.source???: dc.sourceScopus-
Título: dc.titleRevisiting the pharmacodynamic uroselectivity of a1-adrenergic receptor antagonists-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.